Management of adverse events associated with tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia

[1]  Ricardo Pasquini,et al.  Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. , 2010, The New England journal of medicine.

[2]  M. Baccarani,et al.  Efficacy and safety of nilotinib 800 mg daily in early chronic phase Ph+ chronic myeloid leukemia: Results of a phase II trial at 2 years. , 2010 .

[3]  Martin C. Müller,et al.  Potent, transient inhibition of BCR-ABL with dasatinib 100 mg daily achieves rapid and durable cytogenetic responses and high transformation-free survival rates in chronic phase chronic myeloid leukemia patients with resistance, suboptimal response or intolerance to imatinib , 2010, Haematologica.

[4]  Susan Branford,et al.  Phase III, randomized, open-label study of daily imatinib mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: tyrosine kinase inhibitor optimization and selectivity study. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  Susan O'Brien,et al.  Results of dasatinib therapy in patients with early chronic-phase chronic myeloid leukemia. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  Susan O'Brien,et al.  Nilotinib as front-line treatment for patients with chronic myeloid leukemia in early chronic phase. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  J. Cortes,et al.  Dasatinib 100 mg once daily minimizes the occurrence of pleural effusion in patients with chronic myeloid leukemia in chronic phase and efficacy is unaffected in patients who develop pleural effusion , 2010, Cancer.

[8]  J. Radich,et al.  Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  M. Baccarani,et al.  Nilotinib for the frontline treatment of Ph(+) chronic myeloid leukemia. , 2009, Blood.

[10]  E. Domany,et al.  DOWN'S Syndrome Acute Lymphoblastic LEUKEMIA: A HIGHLY Heterogeneous DISEASE DRIVEN by an Aberrant CRLF2/JAK2 Cooperation – A REPORT FROM the Ibfm-STUDY GROUP. , 2009 .

[11]  J. Radich,et al.  International randomized study of interferon Vs STI571 (IRIS) 8-year follow up: Sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib , 2009 .

[12]  J. Radich,et al.  Update On Imatinib-Resistant Chronic Myeloid Leukemia Patients in Chronic Phase (CML-CP) On Nilotinib Therapy at 24 Months: Clinical Response, Safety, and Long-Term Outcomes. , 2009 .

[13]  S. Mustjoki,et al.  Differential Effects of Imatinib and Dasatinib On Immune Effector Cells in Patients with Chronic Myeloid Leukemia (CML). , 2009 .

[14]  Martin C. Müller,et al.  Weekend Drug Holiday of Dasatinib in CML Patients Not Tolerating Standard Dosing Regimens. Reducing Toxicity with Maintained Disease Control. , 2009 .

[15]  D. Marin,et al.  Long Term Adherence to Imatinib Therapy Is the Critical Factor for Achieving Molecular Responses in Chronic Myeloid Leukemia Patients. , 2009 .

[16]  Christophe Massard,et al.  Phase II Study of Dasatinib in Patients with Metastatic Castration-Resistant Prostate Cancer , 2009, Clinical Cancer Research.

[17]  A. Yang,et al.  The occurrence and management of fluid retention associated with TKI therapy in CML, with a focus on dasatinib , 2009, Journal of hematology & oncology.

[18]  J. Plana,et al.  Rare incidence of congestive heart failure in gastrointestinal stromal tumor and other sarcoma patients receiving imatinib mesylate , 2009, Cancer.

[19]  D. Birnbaum,et al.  TET2 mutation is an independent favorable prognostic factor in myelodysplastic syndromes (MDSs). , 2009, Blood.

[20]  J. Radich,et al.  Chronic myelogenous leukemia. , 2009, Hematology. American Society of Hematology. Education Program.

[21]  H. Kantarjian,et al.  Dynamics and management of cytopenias associated with dasatinib therapy in patients with chronic myeloid leukemia in chronic phase after imatinib failure , 2009, Cancer.

[22]  C. Récher,et al.  The new tyrosine-kinase inhibitor and anticancer drug dasatinib reversibly affects platelet activation in vitro and in vivo. , 2009, Blood.

[23]  H. Kantarjian,et al.  Tyrosine kinase inhibitor-induced platelet dysfunction in patients with chronic myeloid leukemia. , 2009, Blood.

[24]  I. Ito,et al.  A case of follicular lymphoma complicated with mesenteric panniculitis , 2009, Hematology Reviews.

[25]  I. Galinsky,et al.  Practical management of dasatinib for maximum patient benefit. , 2009, Clinical journal of oncology nursing.

[26]  S. Geest,et al.  Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study. , 2009, Blood.

[27]  M. Baccarani,et al.  Nilotinib in chronic myeloid leukemia patients in accelerated phase (CML-AP) with imatinib (IM) resistance or intolerance: Longer follow-up results of a phase II study. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  F. Giles,et al.  Serosal inflammation (pleural and pericardial effusions) related to tyrosine kinase inhibitors , 2009, Targeted Oncology.

[29]  J. Cortes,et al.  Dasatinib treatment for Philadelphia chromosome‐positive leukemias , 2009, Cancer.

[30]  J. Radich,et al.  Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia , 2009, Leukemia.

[31]  H. Kantarjian,et al.  Imatinib mesylate dose escalation is associated with durable responses in patients with chronic myeloid leukemia after cytogenetic failure on standard-dose imatinib therapy. , 2009 .

[32]  Ting Yang,et al.  Cardiotoxicity of tyrosine kinase inhibitors in chronic myelogenous leukemia therapy , 2009, Hematology Reviews.

[33]  J. Cayuela,et al.  Imatinib dose escalation for chronic phase–chronic myelogenous leukaemia patients in primary suboptimal response to imatinib 400 mg daily standard therapy , 2009, Leukemia.

[34]  R. Larson,et al.  Efficacy of imatinib dose escalation in patients with chronic myeloid leukemia in chronic phase , 2009, Cancer.

[35]  Rocco Piazza,et al.  Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutants. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  B. Turcq,et al.  Evidence that resistance to nilotinib may be due to BCR-ABL, Pgp, or Src kinase overexpression. , 2008, Cancer research.

[37]  S. Mustjoki,et al.  Clonal expansion of T/NK-cells during tyrosine kinase inhibitor dasatinib therapy , 2008, Leukemia.

[38]  H. Dombret,et al.  Dasatinib 140 Mg Once Daily (QD) Demonstrates Equivalent Efficacy and Improved Safety Compared with 70 Mg Twice Daily (BID) in Patients with Chronic Myeloid Leukemia in Blast Phase (CML-BP): 2-Year Data from CA180-035 , 2008 .

[39]  Richard Pazdur,et al.  Tasigna for Chronic and Accelerated Phase Philadelphia Chromosome–Positive Chronic Myelogenous Leukemia Resistant to or Intolerant of Imatinib , 2008, Clinical Cancer Research.

[40]  Jaspal Kaeda,et al.  Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[41]  Andreas Hochhaus,et al.  Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[42]  D. Marin,et al.  Pleural effusions in patients with chronic myeloid leukaemia treated with dasatinib may have an immune‐mediated pathogenesis , 2008, British journal of haematology.

[43]  D. Marin,et al.  Imatinib use in chronic phase CML in clinical practice: the UNIC study , 2008 .

[44]  R. Larson,et al.  Nilotinib in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in blast crisis (CML-BC) who are resistant or intolerant to imatinib , 2008 .

[45]  R. Stone,et al.  Dasatinib lack of cross intolerance to imatinib in patients (pts) with chronic myelogenous leukemia chronic phase (CML-CP) intolerant to imatinib: a retrospective analysis of safety , 2008 .

[46]  A. Frustaci,et al.  Cardiac events in imatinib mesylate-treated chronic myeloid leukemia patients: A single institution experience. , 2008, Leukemia research.

[47]  Tillmann Krahnke,et al.  Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study. , 2008, Blood.

[48]  H. Tan,et al.  Imatinib mesylate-related fatal acute hepatic failure in a patient with chronic myeloid leukaemia and chronic hepatitis B infection. , 2008, Singapore medical journal.

[49]  S. Fitter,et al.  Long-term imatinib therapy promotes bone formation in CML patients. , 2008, Blood.

[50]  W. Aulitzky,et al.  Therapeutic options for chronic myeloid leukemia: focus on imatinib (Glivec®, Gleevec™) , 2008, Therapeutics and clinical risk management.

[51]  K. Ingersoll,et al.  The impact of medication regimen factors on adherence to chronic treatment: a review of literature , 2008, Journal of Behavioral Medicine.

[52]  R. Pazdur,et al.  Sprycel for Chronic Myeloid Leukemia and Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia Resistant to or Intolerant of Imatinib Mesylate , 2008, Clinical Cancer Research.

[53]  S. Marciano,et al.  Imatinib-induced fatal acute liver failure. , 2007, World journal of gastroenterology.

[54]  M. Baccarani,et al.  Nilotinib Is Associated with Minimal Cross Intolerance to Imatinib in Patients with Imatinib-Intolerant Philadelphia-Positive (Ph+) Chronic Myelogenous Leukemia (CML) in Either Chronic Phase (CP) or Accelerated Phase (AP). , 2007 .

[55]  K. Bhalla,et al.  Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. , 2007, Blood.

[56]  V. Meignin,et al.  Lung abnormalities after dasatinib treatment for chronic myeloid leukemia: a case series. , 2007, American journal of respiratory and critical care medicine.

[57]  R. Munden,et al.  Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[58]  Andreas Hochhaus,et al.  Chronic myeloid leukaemia , 2007, The Lancet.

[59]  Nicholas Moore,et al.  Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia. , 2007, Blood.

[60]  Z. Zahrani,et al.  Imatinib-induced immune hepatitis: Case report and literature review , 2007, Hematology.

[61]  Francisco Cervantes,et al.  Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. , 2006, The New England journal of medicine.

[62]  H. Kantarjian,et al.  Congestive heart failure is a rare event in patients receiving imatinib therapy. , 2006, Blood.

[63]  H. Joensuu,et al.  Imatinib and altered bone and mineral metabolism. , 2006, The New England journal of medicine.

[64]  G. Lyritis,et al.  Imatinib and altered bone and mineral metabolism. , 2006, The New England journal of medicine.

[65]  Brian Walters,et al.  Cardiotoxicity of the cancer therapeutic agent imatinib mesylate , 2006, Nature Medicine.

[66]  J. Tsang,et al.  Prescription compliance and persistency in chronic myelogenous leukemia (CML) and gastrointestinal stromal tumor (GIST) patients (pts) on imatinib (IM). , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[67]  Glenn Heller,et al.  Altered bone and mineral metabolism in patients receiving imatinib mesylate. , 2006, The New England journal of medicine.

[68]  B. Portmann,et al.  Imatinib mesylate as a cause of acute liver failure , 2006, American journal of hematology.

[69]  R. Yamazaki,et al.  Successful management of liver injury caused by imatinib mesylate in a patient with previously untreated chronic myelogenous leukemia in the chronic phase , 2006, Leukemia & lymphoma.

[70]  A. Lippman.  Adherence to medication. , 2005, The New England journal of medicine.

[71]  Kazuya Sato,et al.  Severe Hepatic Injury Caused by Imatinib Mesylate Administered for the Treatment of Chronic Myeloid Leukemia and the Efficacy of Prednisolone for its Management , 2005, International journal of hematology.

[72]  J. Cheng,et al.  Action of the Src family kinase inhibitor, dasatinib (BMS-354825), on human prostate cancer cells. , 2005, Cancer research.

[73]  J. Mestan,et al.  In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. , 2005, Cancer research.

[74]  F. Lee,et al.  BMS-354825 potently inhibits multiple selected oncogenic tyrosine kinases and possesses broad-spectrum antitumor activities in vitro and in vivo , 2005 .

[75]  Donna Neuberg,et al.  Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. , 2005, Cancer cell.

[76]  Ping Chen,et al.  Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. , 2004, Journal of medicinal chemistry.

[77]  Ping Chen,et al.  Overriding Imatinib Resistance with a Novel ABL Kinase Inhibitor , 2004, Science.

[78]  N. Lin,et al.  Fatal hepatic necrosis following imatinib mesylate therapy. , 2003, Blood.

[79]  Mark Rothmann,et al.  Approval summary: imatinib mesylate capsules for treatment of adult patients with newly diagnosed philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[80]  J. Ford,et al.  Practical management of patients with chronic myeloid leukemia receiving imatinib. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[81]  Francisco Cervantes,et al.  Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. , 2003, The New England journal of medicine.

[82]  R. Larson,et al.  Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. , 2002, Blood.

[83]  M. Baccarani,et al.  Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. , 2002, Blood.

[84]  C. Sawyers.  Chronic myeloid leukemia. , 1999, The New England journal of medicine.

[85]  R. Gale,et al.  Chronic myeloid leukemia. , 1992, The American journal of medicine.

[86]  W. Feng,et al.  Treatment Interruptions and Non-Adherence with Imatinib and Associated Healthcare Costs , 2012, PharmacoEconomics.

[87]  M. Gordon.  Dasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia , 2010 .

[88]  Martin C. Müller,et al.  Phase 3 study of dasatinib 140 mg once daily versus 70 mg twice daily in patients with chronic myeloid leukemia in accelerated phase resistant or intolerant to imatinib: 15-month median follow-up. , 2009, Blood.

[89]  R M Stone,et al.  Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib , 2008, Leukemia.

[90]  J. Singer,et al.  UGT1A1 promoter polymorphism increases risk of nilotinib-induced hyperbilirubinemia , 2007, Leukemia.

[91]  R. Piazza,et al.  In reply to 'Cardiotoxicity of the cancer therapeutic agent imatinib mesylate' , 2007, Nature Medicine.

[92]  C. Bokemeyer,et al.  Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies. , 2006, Cancer research.

[93]  R. Brand,et al.  Allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia in Europe 2006: transplant activity, long-term data and current results. An analysis by the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). , 2006, Haematologica.